Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047536 · ClinicalTrials.gov registry record · Phase 1
KZR-261 in Subjects With Advanced Solid Malignancies
A Phase 1 study, sponsored by Kezar Life Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT05047536 is a Phase 1 study that was terminated before completion, run by Kezar Life Sciences. The registered enrollment target is 61 participants.
The verdict
NCT05047536, a Phase 1 study, was terminated before completion, sponsored by Kezar Life Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprised a Part 1 (Dose Escalation) and a Part 2 (2A Dose Expansion and 2B Dose Optimization) in solid organ tumors (melanoma/uveal melanoma, mesothelioma, colorectal cancer, castration-resistant prostate cancer, and "All-Tumors").
Interventions
- DRUG KZR-261
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2025-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05047536
The ClinicalTrials.gov registry entry for NCT05047536 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kezar Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KZR-261 is the first listed.
NCT05047536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05047536 about?
NCT05047536 is a clinical study titled "KZR-261 in Subjects With Advanced Solid Malignancies". A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprised a Part 1 (Dose Escalation) and a Par...
What is the current status of trial NCT05047536?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2021-09-30. Estimated completion is 2025-01-17.
What interventions are being tested in trial NCT05047536?
The interventions under investigation include: KZR-261 (DRUG).
Who is sponsoring clinical trial NCT05047536?
This trial is sponsored by Kezar Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.